Autopsy report · NCT01212627

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

“Determination to stop enrollment made due to funding”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 7 months before it stopped.
• 12 participants enrolled.
• Results were posted on the registry 2 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Angela Taber MD

Sponsor type

University, hospital or other

Conditions

Non-Small Cell Lung Cancer

Interventions

Ridaforolimus

Participants

12

Sites

2

Countries

United States

Trials that died the same way

• Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
  “low enrollment, termination of funding” (82% match in meaning)
• Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia
  “Loss of funding before enrollment.” (75% match in meaning)
• Feasibility and Acceptability of a Remote Glucose Monitoring Program for Pregnant Marshallese Women
  “Funding ended before enrollment” (74% match in meaning)
• Registry for Patients Undergoing Pulmonary Procedures
  “funding/ enrollment” (74% match in meaning)
• ALgorithms Adapted From Remote Monitoring
  “Low enrollment, completion of funding” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.